Abstract
Background
Methods
Results
Discussion
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesReferences
- Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis.J. Clin. Psychiatry. 2017; 78: e264-e278https://doi.org/10.4088/JCP.16r10832
- Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment.J. Clin. Psychiatry. 2017; https://doi.org/10.4088/JCP.tv17016ah4c
- Abnormal Involuntary Movement Scale (117-AIMS), in ECDEU Assessment Manual for Psychopharmacology.1976: 534-537
- Manual for the extrapyramidal symptom rating scale (ESRS).Schizophr. Res. 2005; 76: 247-265https://doi.org/10.1016/j.schres.2005.02.013
- Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.Can. J. Psychiatr. 2005; 50: 541-547https://doi.org/10.1177/070674370505000907
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study.Neurology. 2017; 88: 2003-2010https://doi.org/10.1212/WNL.0000000000003960
Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study. P7-009. The American Psychiatric Association 2017 Annual Meeting. San Diego, California, USA, 2017.
Anderson KE, Stamler D, Davis MD, et al. Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study. P07-010. The American Psychiatric Association 2017 Annual Meeting. San Diego, California, USA, 2017.
- Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.Int. J. Clin. Pract. 2017; 71https://doi.org/10.1111/ijcp.12964
- Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.Int. J. Clin. Pract. 2017; https://doi.org/10.1111/ijcp.13030
- KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia.Am. J. Psychiatry. 2017; 174: 476-484https://doi.org/10.1176/appi.ajp.2017.16091037
- Efficacy of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of a long-term study (KINECT 3 Extension) (S56.005).Neurology. 2017; 88
- Efficacy of Valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder.Psychopharmacol. Bull. 2017; 47: 69-76
- Long-term safety and tolerability of Valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder.Psychopharmacol. Bull. 2017; 47: 61-68
- Efficacy of Valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder.Psychopharmacol. Bull. 2017; 47: 53-60
- Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.Acta Psychiatr. Scand. 1996; 94: 118-124
- Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.J. Clin. Psychopharmacol. 2000; 20: 188-194
- Prospective study of tardive dyskinesia in the elderly: rates and risk factors.Am. J. Psychiatry. 1998; 155: 1521-1528https://doi.org/10.1176/ajp.155.11.1521
- Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.Arch. Gen. Psychiatry. 1995; 52: 756-765
- Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patients.Neuropsychopharmacology. 2011; 36: 1738-1746https://doi.org/10.1038/npp.2011.55
- Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.Am. J. Psychiatry. 2004; 161: 414-425https://doi.org/10.1176/appi.ajp.161.3.414
- Tardive dyskinesia and new antipsychotics.Curr. Opin. Psychiatry. 2008; 21: 151-156https://doi.org/10.1097/YCO.0b013e3282f53132
- Gender differences in tardive dyskinesia: a critical review of the literature.Schizophr. Bull. 1992; 18: 701-715
- Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis.Mov. Disord. 2009; 24: 2309-2315https://doi.org/10.1002/mds.22707
- Drug-drug interactions with antipsychotics.CNS Spectr. 2007; 12: 6-9
- Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Mol. Psychiatry. 2008; 13: 544-556https://doi.org/10.1038/sj.mp.4002142
- The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.Health Technol. Assess. 2010; 14 (iii): 1-157https://doi.org/10.3310/hta14030
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Pharm. J. 2010; 11 (iii): 1-14https://doi.org/10.1038/tpj.2010.73
- Genetics of common antipsychotic-induced adverse effects.Mol. Neuropsychiatry. 2016; 2: 61-78https://doi.org/10.1159/000445802
- The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk.Int. J. Neurosci. 2016; 126: 1044-1050https://doi.org/10.3109/00207454.2015.1089504
- Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.J. Psychiatr. Res. 2013; 47: 1760-1765https://doi.org/10.1016/j.jpsychires.2013.07.025
- BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.Schizophr. Res. 2014; 152: 365-372https://doi.org/10.1016/j.schres.2013.12.011
- Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.Psychiatry Res. 2004; 127: 1-7https://doi.org/10.1016/j.psychres.2004.03.011
- Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.Schizophr. Res. 2006; 83: 185-192https://doi.org/10.1016/j.schres.2006.01.010
- Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2013; 46: 207-213https://doi.org/10.1016/j.pnpbp.2012.10.018
- Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.Schizophr. Res. 2005; 80: 33-43https://doi.org/10.1016/j.schres.2005.07.034
- Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.Neuropsychopharmacology. 1993; 8: 233-239https://doi.org/10.1038/npp.1993.26
- On the use of antipsychotic medication in an intellectual disability (ID) community caseload.Psychiatr. Danub. 2017; 29: 578-583
- Antipsychotic use trends in youth with autism Spectrum disorder and/or intellectual disability: a meta-analysis.J. Am. Acad. Child Adolesc. Psychiatry. 2016; 55 (e4): 456-468https://doi.org/10.1016/j.jaac.2016.03.012
- Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use.Res. Dev. Disabil. 2010; 31: 108-116https://doi.org/10.1016/j.ridd.2009.08.002
- Tardive dyskinesia: who is at risk?.Acta Psychiatr. Scand. 1997; 96: 206-216
- Tardive dyskinesia and deficit schizophrenia.Acta Psychiatr. Scand. 2011; 124: 357-362https://doi.org/10.1111/j.1600-0447.2011.01751.x
- Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder.Asian J. Psychiatr. 2017; 32: 92-98https://doi.org/10.1016/j.ajp.2017.12.001
- Tardive dyskinesia: prevalence, incidence, and risk factors.Psychopharmacology Suppl. 1985; 2: 72-78
- As a predictor in the development of tardive dyskinesia.Biol. Psychiatry. 1984; 19: 441-444
- Tardive dyskinesia and the primary psychiatric diagnosis.Psychosomatics. 1984; 25: 135-138https://doi.org/10.1016/S0033-3182(84)73083-0
- Cognitive functions in tardive dyskinesia.Psychol. Med. 1983; 13: 671-674
- Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia.Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2013; 46: 71-77https://doi.org/10.1016/j.pnpbp.2013.06.013
- Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.World Psychiatry. 2016; 15: 166-174https://doi.org/10.1002/wps.20309
- Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries.BMC Med. 2016; 14: 189https://doi.org/10.1186/s12916-016-0734-z
- Tardive dyskinesia and diabetes mellitus.Psychopharmacol. Bull. 1992; 28: 281-286
- A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults.Bipolar Disord. 2015; 17: 575-597https://doi.org/10.1111/bdi.12319
- Smoking and tardive dyskinesia in male patients with chronic schizophrenia.Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011; 35: 1765-1769https://doi.org/10.1016/j.pnpbp.2011.06.006
- Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.Eur. Psychiatry. 2009; 24: 33-40https://doi.org/10.1016/j.eurpsy.2008.07.007
- Substance misuse in patients with schizophrenia: epidemiology and management.Drugs. 2002; 62: 743-755
- Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: systematic review and meta-analysis.J. Affect. Disord. 2016; 206: 331-349https://doi.org/10.1016/j.jad.2016.07.011
- Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings.Psychiatry Clin. Neurosci. 2013; 67: 367-383https://doi.org/10.1111/pcn.12072
- Increased tardive dyskinesia in alcohol-abusing schizophrenic patients.Compr. Psychiatry. 1992; 33: 121-122
- Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis.Schizophr. Res. 2009; 113: 181-188https://doi.org/10.1016/j.schres.2009.06.010
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Psychiatry. 2017; 4: 595-604https://doi.org/10.1016/S2215-0366(17)30236-5
- side effects are unacceptable.Eur. Neuropsychopharmacol. 2001; 11: S397-403
- Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.Aust. N Z J. Psychiatry. 2004; 38: 445-449https://doi.org/10.1080/j.1440-1614.2004.01382.x
- Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European schizophrenia outpatient health outcomes (SOHO) study.Am. J. Psychiatry. 2006; 163: 1438-1440https://doi.org/10.1176/ajp.2006.163.8.1438
- diagnoses for tardive dyskinesia.Arch. Gen. Psychiatry. 1982; 39: 486-487
- Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.Biol. Psychiatry. 1995; 38: 713-719https://doi.org/10.1016/0006-3223(95)00082-8
- Risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study.Arch. Gen. Psychiatry. 1993; 50: 723-733
- Patterns of psychotropic drug use and tardive dyskinesia.J. Clin. Psychopharmacol. 1984; 4: 41-45
- Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.Asian J. Psychiatr. 2014; 9: 31-35https://doi.org/10.1016/j.ajp.2013.12.010
- Intermittent neuroleptic treatment and risk for tardive dyskinesia: curacao extrapyramidal syndromes study III.Am. J. Psychiatry. 1998; 155: 565-567https://doi.org/10.1176/ajp.155.4.565
- Anticholinergic medication for neuroleptic-induced tardive dyskinesia.Cochrane Database Syst. Rev. 2000; 2CD000204https://doi.org/10.1002/14651858.CD000204
- Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study.Br. J. Psychiatry. 1984; 145: 304-310
- Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?.J. Psychopharmacol. 2012; 26: 1167-1174https://doi.org/10.1177/0269881112447988
- Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.Health Technol. Assess. 2017; 21: 1-218https://doi.org/10.3310/hta21430
- Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2000.2000
- Smoking and mental illness: a population-based prevalence study.JAMA. 2000; 284: 2606-2610
- Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.Am. J. Addict. 2007; 16: 260-268https://doi.org/10.1080/10550490701389658
- Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.J. Psychopharmacol. 2012; 26: 189-195https://doi.org/10.1177/0269881111408957
- Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials.J Clin Psychiatry. 2013; 74: e642-54https://doi.org/10.4088/JCP.12r08178
- Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis.Psychiatry Res. 2017; 250: 17-24https://doi.org/10.1016/j.psychres.2017.01.049
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.World Psychiatry. 2017; 16: 163-180https://doi.org/10.1002/wps.20420
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Ther. Clin. Risk Manag. 2017; 13: 757-777https://doi.org/10.2147/TCRM.S117321
- Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia.Acta Psychiatr. Scand. 2017; https://doi.org/10.1111/acps.12825
- Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.Schizophr. Res. 2017; https://doi.org/10.1016/j.schres.2017.07.022
- Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.J Clin Psychiatry. 1987; 48: 263-267
- Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.J Clin Psychiatry. 1997; 58: 318-322
- Tardive dyskinesia, clozapine, and treatment response.Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 1998; 22: 567-573
- Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.World J. Biol. Psychiatry. 2009; 10: 919-924https://doi.org/10.1080/15622970802481895
Article info
Publication history
Footnotes
☆This article is part of the Special Issue Tardive Syndromes and Their Management edited by Robert A. Hauser and Daniel D. Truong.